Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7%

Ascendis Pharma A/S (NASDAQ:ASND) shares traded up 7% during mid-day trading on Wednesday . The company traded as high as $131.72 and last traded at $131.40. 713,567 shares were traded during mid-day trading, an increase of 82% from the average session volume of 391,167 shares. The stock had previously closed at $122.85.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Citigroup increased their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.88.

Ascendis Pharma A/S Trading Up 0.7 %

The company’s fifty day simple moving average is $140.60 and its two-hundred day simple moving average is $131.36.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The firm had revenue of $103.11 million for the quarter, compared to analyst estimates of $85.72 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -5.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds have recently modified their holdings of ASND. GAMMA Investing LLC acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $25,000. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S in the first quarter worth approximately $36,000. Quadrant Capital Group LLC lifted its position in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares in the last quarter. Finally, Signaturefd LLC lifted its position in Ascendis Pharma A/S by 31.9% during the third quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 193 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.